ORICファーマシューティカルズ
ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.38 | $0 | -$32M |
| 2026 Q1 | -0.34 | $0 | -$32M |
| 2025 Q4 | -0.30 | $0 | -$23M |
| 2025 Q3 | -0.33 | $0 | -$25M |
| 2025 Q2 | -0.47 | $0 | -$31M |
| 2025 Q1 | -0.42 | $0 | -$33M |
| 2024 Q4 |
| -0.51 |
| $0 |
| -$28M |
| 2024 Q3 | -0.49 | $0 | -$29M |